Numerous studies have suggested that the deregulation of the PI3K/AKT signaling pathway was responsible for increased de novo lipogenesis and then exacerbated nonesterified fatty acid (FFA) flux to the liver by increasing lipolysis, which finally led to NASH [56,57]. Here, AKT1 is linked to metabolic dysfunction-associated steatohepatitis.